Azitra (AZTR) Receivables (2022 - 2026)

Azitra (AZTR) posted Receivables of $5108.0 for Q1 2026, up 460.09% on a QoQ basis from $912.0 in Q4 2025.

Azitra (AZTR) Receivables (2022 - 2026) Analysis & Trends

Azitra's Receivables history runs 5 years deep, the most recent figure standing at $5108.0 for Q1 2026.

Quarterly Receivables changed N/A year-over-year to $5108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5108.0 (changed N/A YoY) and the FY2025 annual result came in at $912.0, up 291.42% from the prior year.
Receivables was $5108.0 for Q1 2026 at Azitra, up from $912.0 in the prior quarter.
Across five years, Receivables topped out at $885120.0 in Q2 2023 and bottomed at $233.0 in Q4 2024.
A 5-year average of $167826.2 and a median of $3482.5 in 2024 frame the typical range for Receivables.
Annual changes were most pronounced in 2024 — Receivables tumbled 99.87% — and 2025, when it soared 291.42%.
Azitra's Receivables stood at $350000.0 in 2022, then plunged by 71.93% to $98255.0 in 2023, then sank by 99.76% to $233.0 in 2024, then surged by 291.42% to $912.0 in 2025, then jumped by 460.09% to $5108.0 in 2026.
Business Quant data shows AZTR's Receivables at $5108.0 in Q1 2026, $912.0 in Q4 2025, and $233.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Nanobiotix	1,769.80 Bn	1,769.74 Bn	-	4.86 Mn
2	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-	-
3	BeOne Medicines	473.64 Bn	468.85 Bn	1.35 Bn	938.02 Mn
4	Vertex Pharmaceuticals	123.74 Bn	116.49 Bn	2.59 Bn	2.00 Bn
5	Regeneron Pharmaceuticals	71.73 Bn	62.97 Bn	3.31 Bn	5.73 Bn
6	Belite Bio	62.10 Bn	62.10 Bn	-	-
7	Argenx Se	54.68 Bn	49.49 Bn	1.41 Bn	1.93 Bn
8	Alnylam Pharmaceuticals	38.13 Bn	35.12 Bn	959.66 Mn	883.96 Mn
9	Revolution Medicines	36.21 Bn	36.21 Bn	-	-
10	Azitra	2.03 Mn	2.03 Mn	-	5,108.00

Download Data